Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma

Reder, Henrike; Taferner, Victor F.; Wittekindt, Claus; Bräuninger, Andreas; Speel, Ernst‐Jan M.; Gattenlöhner, Stefan; Wolf, Gregor; Klußmann, Jens Peter; Wuerdemann, Nora; Wagner, Steffen

doi:10.1016/j.jmoldx.2020.08.002

Cited by 34 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nine studies ( n = 1353, 77.6% HPV+) examined the diagnostic accuracy of HPV detection by liquid biopsy using blood samples. One study collected the blood samples both at time of diagnosis and during treatment and evaluated the accuracy of the test regardless of the time of blood collection [ 35 ], the other eight studies collected blood samples before treatment initiation [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ]. Five studies tested HPV in plasma [ 36 , 37 , 38 , 39 , 40 ], two studies reported detection in blood [ 35 , 41 ] and two studies investigated HPV in serum [ 42 , 43 ].…”

Section: Resultsmentioning

confidence: 99%

“…In the pooled analysis of sensitivity and specificity, the overall sensitivity was 81.4% (95% CI 62.9–91.9), and the overall specificity was 94.8% (95% CI 91.4–96.9) covering all studies regardless of detection method and reference [ 35 , 36 , 38 , 40 , 41 , 42 , 43 ] (excluding the two studies with non-OPSCC patients [ 37 , 39 ]).…”

Section: Resultsmentioning

confidence: 99%

“…The study addressing diagnostic accuracy of HPV expression in CtCs had a significantly lower sensitivity compared to the remaining studies (Figure 4). In the pooled analysis of sensitivity and specificity, the overall sensitivity was 81.4% (95% CI 62.9-91.9), and the overall specificity was 94.8% (95% CI 91.4-96.9) covering all studies regardless of detection method and reference [35,36,38,[40][41][42][43] (excluding the two studies with non-OPSCC patients [37,39]).…”

Section: Diagnostic Accuracy Of Detecting Hpv In Blood Samplesmentioning

confidence: 99%

“…Three studies used p16 IHC combined with HPV DNA as reference [44,46,47], one study only used p16 IHC as reference [34] and one study used mRNA E6 and E7 as reference [45]. In the pooled analysis of sensitivity and specificity, the overall sensitivity was 81.4% (95% CI 62.9-91.9), and the overall specificity was 94.8% (95% CI 91.4-96.9) covering all studies regardless of detection method and reference [35,36,38,[40][41][42][43] (excluding the two studies with non-OPSCC patients [37,39]).…”

Section: Diagnostic Accuracy Of Detecting Hpv In Oral Samplesmentioning

confidence: 99%

See 3 more Smart Citations

Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis

Jakobsen

Carlander

Bendtsen

et al. 2021

Viruses

View full text Add to dashboard Cite

The aim of the study was to evaluate the diagnostic accuracy of Human Papillomavirus (HPV) techniques in oropharyngeal cancer. PubMed, EMBASE, the Cochrane Library and clinicaltrials.org were systematically searched for studies reporting methods of HPV detection. Primary outcomes were sensitivity and specificity of HPV detection. In this case, 27 studies were included (n = 5488, 41.6% HPV+). In this case, 13 studies evaluated HPV detection in tumour tissue, nine studies examined HPV detection in blood samples and five studies evaluated HPV detection in oral samples. Accuracy of HPV detection in tumour tissue was high for all detection methods, with pooled sensitivity ranging from 81.1% (95% CI 71.9–87.8) to 93.1% (95% CI 87.4–96.4) and specificity ranging from 81.1% (95% CI 71.9–87.8) to 94.9% (95% CI 79.1–98.9) depending on detection methods. Overall accuracy of HPV detection in blood samples revealed a sensitivity of 81.4% (95% CI 62.9–91.9) and a specificity of 94.8% (95% CI 91.4–96.9). In oral samples pooled sensitivity and specificity were lower (77.0% (95% CI 68.8–83.6) and 74.0% (95% CI 58.0–85.4)). In conclusion, we found an overall high accuracy for HPV detection in tumour tissue regardless of the HPV detection method used. HPV detection in blood samples may provide a promising new way of HPV detection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Diagnostic Accuracy Of Detecting Hpv In Blood Samplesmentioning

confidence: 99%

Section: Diagnostic Accuracy Of Detecting Hpv In Oral Samplesmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis

Jakobsen

Carlander

Bendtsen

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…Studies have begun examining the ability of HPV ctDNA plasma presence to detect disease recurrence in HPV-positive OPSCC with promising accuracy [ 44 , 45 ]. In a prospective clinical trial of 115 HPV-positive OPSCC patients, Chera et al demonstrated that two consecutive positive HPV ctDNA blood tests during posttreatment surveillance was highly indicative of disease recurrence [ 26 ].…”

Section: Ctdna Utility In Hpv-positive Head and Neck Cancermentioning

confidence: 99%

The Promise of Circulating Tumor DNA in Head and Neck Cancer

Aulakh

Silverman

Young

et al. 2022

Cancers

View full text Add to dashboard Cite

As the seventh most common cancer globally, head and neck cancers (HNC) exert considerable disease burden, with an estimated 277,597 deaths worldwide in 2020 alone. Traditional risk factors for HNC include tobacco, alcohol, and betel nut; more recently, human papillomavirus has emerged as a distinct driver of disease. Currently, limitations of cancer screening and surveillance methods often lead to identifying HNC in more advanced stages, with associated poor outcomes. Liquid biopsies, in particular circulating tumor DNA (ctDNA), offer the potential for enhancing screening, early diagnosis, and surveillance in HNC patients, with potential improvements in HNC patient outcomes. In this review, we examine current methodologies for detecting ctDNA and highlight current research illustrating viral and non-viral ctDNA biomarker utilities in HNC screening, diagnosis, treatment response, and prognosis. We also summarize current challenges and future directions for ctDNA testing in HNC patients.

show abstract

Circulating tumor HPV DNA as a specific biomarker for cervical cancer

Wu,

Sun,

Sun

et al. 2024

Intl J Gynecology & Obste

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to determine whether circulating tumor human papillomavirus (HPV) DNA is a potential specific biomarker for cervical cancer (CC).MethodsThis retrospective matched study included 87 patients with cervical intraepithelial neoplasia (CIN), 29 CC patients (FIGO IA1‐IVA) and 29 HPV‐negative controls at Yuhuangding Hospital of Qingdao University (from July 2022 to September 2023). The digital droplet PCR (ddPCR) was used to detect and quantify ctHPV DNA in the plasma of patients with HPV16, 18, 33, 52, or 58‐associated CC.ResultsThe ctHPV DNA was exclusively detectable in HPV‐positive samples, with no detection in patients across various CIN stages (n = 87) or HPV‐negative controls (n = 29). Additionally, ctHPV DNA was identified in nine out of 10 late‐stage patients (90%) and six out of 19 early‐stage patients (31.6%).ConclusionThe ctHPV DNA serves as a specific biomarker for the diagnosis CC. Additionally, this discovery addresses the knowledge gap in ctHPV DNA research in the early stages of CC and promotes clinical diagnosis and treatment strategies.

show abstract

Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma

Cited by 34 publications

References 46 publications

Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis

Diagnostic Accuracy of HPV Detection in Patients with Oropharyngeal Squamous Cell Carcinomas: A Systematic Review and Meta-Analysis

The Promise of Circulating Tumor DNA in Head and Neck Cancer

Circulating tumor HPV DNA as a specific biomarker for cervical cancer

Contact Info

Product

Resources

About